5 November 2018 - CADTH has published its initial recommendation on the use of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumours have certain epidermal growth factor receptor mutations.

pERC Expert Review Committee has recommended the use of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor mutations (exon 19 deletion or exon 21 (L858R)) only if both of the following conditions are met:

• Cost-effectiveness is improved to an acceptable level
  
• Feasibility of adoption (budget impact) is addressed
  

Read CADTH initial recommendation for osimertinib mesylate